Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Supplemental Figure 2. MAPK pathway signature is specifically inhibited on treatment (A). Differential expression of 11 PROGENy (pathway) scores between pre and post-treatment samples (B). Only MAPK and EGFR scores are statistically significant (rank-sum test).